Wikipedia

Purinergic receptor

(Redirected from Purine receptor)

Purinergic receptors, also known as purinoceptors, are a family of plasma membrane molecules that are found in almost all mammalian tissues.[1] Within the field of purinergic signalling, these receptors have been implicated in learning and memory, locomotor and feeding behavior, and sleep.[2] More specifically, they are involved in several cellular functions, including proliferation and migration of neural stem cells, vascular reactivity, apoptosis and cytokine secretion.[2][3] These functions have not been well characterized and the effect of the extracellular microenvironment on their function is also poorly understood.

Geoff Burnstock originally separated purinoceptors into P1 adenosine receptors and P2 nucleotide (ATP, ADP) receptors.[4] P2 receptors were later subdivided into P2X, P2Y, P2T, and P2Z receptors.[5] Subclasses X and Y mediated vasoconstriction and vasodilation, respectively, in the smooth muscle of some arteries. They had been observed in blood vessels, smooth muscle, heart, hepatocytes, and parotid acinar cells. Subclass T was only observed in thrombocytes, platelets and megakaryocytes. Subclass Z required ~100 μM-ATP for activation, where the previous classes required <1 μM. They had been observed in mast cells and lymphocytes.

In the early 1990s, purinoceptors were cloned and characterized, and the P2 subclasses were redefined.[4] Now, P2 receptors are classified based on structure: P2X are ionotropic and P2Y are metabotropic. Appropriately, P2Z was reclassified as P2X7[6] and P2T was reclassified as P2Y1.[7]

3 classes of purinergic receptors

edit
Name Activation Class
P1 receptors adenosine G protein-coupled receptors
P2Y receptors nucleotides G protein-coupled receptors
P2X receptors ATP ligand-gated ion channel

There are three known distinct classes of purinergic receptors, known as P1, P2X, and P2Y receptors.

P2X receptors

edit
Main article: P2X purinoreceptor

P2X receptors are ligand-gated ion channels, whereas the P1 and P2Y receptors are G protein-coupled receptors. These ligand-gated ion channels are nonselective cation channels responsible for mediating excitatory postsynaptic responses, similar to nicotinic and ionotropic glutamate receptors.[8] P2X receptors are distinct from the rest of the widely known ligand-gated ion channels, as the genetic encoding of these particular channels indicates the presence of only two transmembrane domains within the channels.[1] These receptors are greatly distributed in neurons and glial cells throughout the central and peripheral nervous systems.[1] P2X receptors mediate a large variety of responses including fast transmission at central synapses, contraction of smooth muscle cells, platelet aggregation, macrophage activation, and apoptosis.[2][9] Moreover, these receptors have been implicated in integrating functional activity between neurons, glial, and vascular cells in the central nervous system, thereby mediating the effects of neural activity during development, neurodegeneration, inflammation, and cancer.[2] The physiological modulator Zn2+ allosterically enhances ATP-induced inward cation currents in the P2X4 receptor by binding to cysteine 132 and cystine 149 residues on the extracellular domain of the P2X4 protein.[10][11]

P2Y and P1 receptors

edit

Both of these metabotropic receptors are distinguished by their reactivity to specific activators. P1 receptors are preferentially activated by adenosine and P2Y receptors are preferentially more activated by ATP. P1 and P2Y receptors are known to be widely distributed in the brain, heart, kidneys, and adipose tissue. Xanthines (e.g. caffeine) specifically block adenosine receptors, and are known to induce a stimulating effect to one's behavior.[12]

Inhibitors

edit

Inhibitors of purinergic receptors include clopidogrel, prasugrel and ticlopidine, as well as ticagrelor. All of these are antiplatelet agents that block P2Y12 receptors.

Effects on chronic pain

edit

Data obtained from using P2 receptor-selective antagonists has produced evidence supporting ATP's ability to initiate and maintain chronic pain states after exposure to noxious stimuli. It is believed that ATP functions as a pronociceptive neurotransmitter, acting at specific P2X and P2Y receptors in a systemized manner, which ultimately (as a response to noxious stimuli) serve to initiate and sustain heightened states of neuronal excitability. This recent knowledge of purinergic receptors' effects on chronic pain provide promise in discovering a drug that specifically targets individual P2 receptor subtypes. While some P2 receptor-selective compounds have proven useful in preclinical trials, more research is required to understand the potential viability of P2 receptor antagonists for pain.[13]

Recent research has identified a role for microglial P2X receptors in neuropathic pain and inflammatory pain, especially the P2X4 and P2X7 receptors.[14][15][16][17][18]

Effects on cytotoxic edema

edit

Purinergic receptors have been suggested to play a role in the treatment of cytotoxic edema and brain infarctions. It was found that with treatment of the purinergic ligand 2-methylthioladenosine 5' diphosphate (2-MeSADP), which is an agonist and has a high preference for the purinergic receptor type 1 isoform (P2Y1R), significantly contributes to the reduction of an ischemic lesions caused by cytotoxic edema. Further pharmacological evidence has suggested that 2MeSADP protection is controlled by enhanced astrocyte mitochondrial metabolism through increased inositol triphosphate-dependent calcium release. There is evidence suggesting a relationship between the levels of ATP and cytotoxic edema, where low ATP levels are associated with an increased prevalence of cytotoxic edema. It is believed that mitochondria play an essential role in the metabolism of astrocyte energy within the penumbra of ischemic lesions. By enhancing the source of ATP provided by mitochondria, there could be a similar 'protective' effect for brain injuries in general.[19]

Effects on diabetes

edit

Purinergic receptors have been implicated in the vascular complications associated with diabetes due to the effect of high-glucose concentration on ATP-mediated responses in human fibroblasts.[20]

See also

edit

References

edit
  1. ^ a b c North RA (October 2002). "Molecular physiology of P2X receptors". Physiological Reviews. 82 (4): 1013–1067. doi:10.1152/physrev.00015.2002. PMID 12270951.
  2. ^ a b c d Burnstock G (2013). "Introduction to Purinergic Signalling in the Brain". Glioma Signaling. Advances in Experimental Medicine and Biology. Vol. 986. pp. 1–12. doi:10.1007/978-94-007-4719-7_1. ISBN 978-94-007-4718-0. PMID 22879061.
  3. ^ Ulrich H, Abbracchio MP, Burnstock G (September 2012). "Extrinsic purinergic regulation of neural stem/progenitor cells: implications for CNS development and repair". Stem Cell Reviews and Reports. 8 (3): 755–767. doi:10.1007/s12015-012-9372-9. PMID 22544361. S2CID 10616782.
  4. ^ a b Burnstock G (January 2014). "Purinergic signalling: from discovery to current developments". Experimental Physiology. 99 (1): 16–34. doi:10.1113/expphysiol.2013.071951. PMC 4208685. PMID 24078669.
  5. ^ Gordon JL (January 1986). "Extracellular ATP: effects, sources and fate". The Biochemical Journal. 233 (2): 309–319. doi:10.1042/bj2330309. PMC 1153029. PMID 3006665.
  6. ^ Surprenant A, Rassendren F, Kawashima E, North RA, Buell G (May 1996). "The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7)". Science. 272 (5262): 735–738. doi:10.1126/science.272.5262.735. PMID 8614837.
  7. ^ Léon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C (February 1997). "The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells". FEBS Letters. 403 (1): 26–30. Bibcode:1997FEBSL.403...26L. doi:10.1016/S0014-5793(97)00022-7. PMID 9038354.
  8. ^ Kaczmarek-Hájek K, Lörinczi E, Hausmann R, Nicke A (September 2012). "Molecular and functional properties of P2X receptors--recent progress and persisting challenges". Purinergic Signalling. 8 (3): 375–417. doi:10.1007/s11302-012-9314-7. PMC 3360091. PMID 22547202.
  9. ^ Burnstock G, Fredholm BB, North RA, Verkhratsky A (June 2010). "The birth and postnatal development of purinergic signalling". Acta Physiologica. 199 (2): 93–147. doi:10.1111/j.1748-1716.2010.02114.x. PMID 20345419. S2CID 25734771.
  10. ^ Acuña-Castillo C, Morales B, Huidobro-Toro JP (April 2000). "Zinc and copper modulate differentially the P2X4 receptor". Journal of Neurochemistry. 74 (4): 1529–1537. doi:10.1046/j.1471-4159.2000.0741529.x. PMID 10737610. S2CID 19142246.
  11. ^ Zemkova H (December 2020). "Special Issue of International Journal of Molecular Sciences (IJMS) "Purinergic P2 Receptors: Structure and Function"". International Journal of Molecular Sciences. 22 (1): 383. doi:10.3390/ijms22010383. PMC 7796286. PMID 33396540.
  12. ^ Purves D, Augustine GJ, Fitzpatrick D, Katz L, LaMantia AS, McNamara J, Williams SM, eds. (2001). Neuroscience (2nd ed.). Sunderland (MA): Sinauer Associates. ISBN 0-87893-742-0.
  13. ^ Jarvis MF (January 2010). "The neural-glial purinergic receptor ensemble in chronic pain states". Trends in Neurosciences. 33 (1): 48–57. doi:10.1016/j.tins.2009.10.003. PMID 19914722. S2CID 26035589.
  14. ^ Tsuda M, Kuboyama K, Inoue T, Nagata K, Tozaki-Saitoh H, Inoue K (June 2009). "Behavioral phenotypes of mice lacking purinergic P2X4 receptors in acute and chronic pain assays". Molecular Pain. 5: 28. doi:10.1186/1744-8069-5-28. PMC 2704200. PMID 19515262.
  15. ^ Ulmann L, Hirbec H, Rassendren F (July 2010). "P2X4 receptors mediate PGE2 release by tissue-resident macrophages and initiate inflammatory pain". The EMBO Journal. 29 (14): 2290–2300. doi:10.1038/emboj.2010.126. PMC 2910276. PMID 20562826.
  16. ^ Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, et al. (August 2003). "P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury". Nature. 424 (6950): 778–783. doi:10.1038/nature01786. PMID 12917686. S2CID 4358793.
  17. ^ Kobayashi K, Takahashi E, Miyagawa Y, Yamanaka H, Noguchi K (October 2011). "Induction of the P2X7 receptor in spinal microglia in a neuropathic pain model". Neuroscience Letters. 504 (1): 57–61. doi:10.1016/j.neulet.2011.08.058. PMID 21924325. S2CID 32284927.
  18. ^ Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, et al. (April 2005). "Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain". Pain. 114 (3): 386–396. doi:10.1016/j.pain.2005.01.002. PMID 15777864. S2CID 21486673.
  19. ^ Zheng W, Watts LT, Holstein DM, Prajapati SI, Keller C, Grass EH, et al. (December 2010). "Purinergic receptor stimulation reduces cytotoxic edema and brain infarcts in mouse induced by photothrombosis by energizing glial mitochondria". PLOS ONE. 5 (12): e14401. Bibcode:2010PLoSO...514401Z. doi:10.1371/journal.pone.0014401. PMC 3008710. PMID 21203502.
  20. ^ Solini A, Chiozzi P, Falzoni S, Morelli A, Fellin R, Di Virgilio F (October 2000). "High glucose modulates P2X7 receptor-mediated function in human primary fibroblasts". Diabetologia. 43 (10): 1248–1256. doi:10.1007/s001250051520. PMID 11079743.
edit
Retrieved from "https://en.wiki.x.io/w/index.php?title=Purinergic_receptor&oldid=1246644588"